Ibandronate
- Generic Name
- Ibandronate
- Brand Names
- Bondronat, Boniva, Bonviva, Iasibon, Ibandronic acid Accord, Ibandronic Acid Sandoz, Ibandronic Acid Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C9H23NO7P2
- CAS Number
- 114084-78-5
- Unique Ingredient Identifier
- UMD7G2653W
- Background
Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid. It is used to prevent and treat postmenopausal osteoporosis. Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.
...
- Indication
For the treatment and prevention of osteoporosis in postmenopausal women.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Osteoporosis
- Associated Therapies
- -
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 341
- Registration Number
- NCT02598440
A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT02564107
A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 97
- Registration Number
- NCT02561039
A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2015-09-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 182
- Registration Number
- NCT02553707
Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis
Completed
- Conditions
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2014-10-22
- Target Recruit Count
- 700
- Registration Number
- NCT02271204
Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Brigitte Jolles, MD
- Target Recruit Count
- 8
- Registration Number
- NCT02114489
- Locations
- 🇨🇭
Lausanne University Hospital, Lausanne, Vaud, Switzerland
BONVIVA(Ibandronate) PMS(Post-marketing Surveillance )
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2012-11-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 659
- Registration Number
- NCT01381393
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
Efficacy of Monthly Ibandronate in Women With RA and Reduced Bone Mineral Density Receiving Long-term Steroids
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- Yeong-Wook Song
- Target Recruit Count
- 167
- Registration Number
- NCT01287533
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 684815
- Registration Number
- NCT01077817
A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 833
- Registration Number
- NCT00936897
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath